ARTICLES BY YULIA PRIVOLNEV

• The Brexit Deal And Its Impact On The Pharmaceutical Industry

  11/30/2018

  According to trade groups, approximately 45 million packs of medicines leave the U.K. for Europe every month, and 37 million go in the opposite direction. In a year, that’s almost 1 billion packs of medicines. What those borders would look like after a Brexit deal would significantly impact major industries in the U.K. and EU economies.

• Should Pharma Companies Even Care About Brexit?

  1/29/2018

  It is difficult to assess the ultimate impact of Brexit on the pharmaceutical industry when so much remains unknown. However, many would argue it is exactly this uncertainty that makes Brexit so disruptive. 

• Preparing For Brexit: Advice From The EMA

  12/18/2017

  The U.K.’s Business, Energy and Industrial Strategy (BEIS) parliamentary committee announced it is investigating the implications of Brexit for the U.K.’s pharmaceutical market, amidst fears Brexit will threaten "the cost of medicines, investment in the United Kingdom and access to new and innovative research and products."

   

• Brexit & The Biopharma Industry: 3 Important Developments To Watch

  8/25/2017

  There have been considerable updates in the Brexit situation since April 2017, including, the surprising result of the U.K. general election. If anything, news regarding Brexit and the biopharma industry has started to heat up in recent months, and there have been a number of relevant developments that manufacturers must keep their eye on.

• Brexit & The Biopharma Industry: What Happens Next?

  4/24/2017

  For all the talk of “hard Brexit” and “soft Brexit” and discussion surrounding the post-Brexit relationship between the U.K. and EU, we still don't know much more than we did a year ago. 

• Brexit’s Impact On The Global Pharmaceutical Industry: Market Authorization & Pricing

  7/12/2016

  The Brexit referendum has resulted in instability and uncertainty for many aspects of British society, including the pharmaceutical industry. As we discussed in Part 1 of this two-part article, life sciences funding and the common market are at risk, and with it billions of dollars in research funding and imports/exports. In this article, we will explore the UK’s future relationship with the EU after exit, which will affect many facets of the worldwide pharmaceutical industry, from marketing authorization to global pricing trends.

• Brexit’s Impact On The Global Pharmaceutical Industry: Future Access To The EU Common Market

  7/6/2016

  On June 23, 2016, the voters of the United Kingdom voted to leave the European Union in an advisory referendum colloquially referred to as the “Brexit” (British exit) vote. The aftermath of the vote has been chaotic — from financial troubles that have seen the British economy and currency plummet, to political bedlam that has led to a number of political casualties, including the Prime Minister and his heir apparent. While analysts, journalists, and the public all discuss the impact of Brexit on the UK and the path forward, few realize the implications that the vote will have on healthcare, and the pharmaceutical industry in particular.